Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

Marek Kulus(Medical University of Warsaw), Martin Blogg(Novartis (United Kingdom)), Elizabeth García(Fundación Santa Fe de Bogotá), Carlos Fernández Vidaurre(Novartis (United States)), Jean‐Louis Hébert(Sorbonne Université), A. Fowler Taylor(Novartis (United States))

Current Medical Research and Opinion

April 8, 2010

10.1185/03007991003771338

Cited by 92

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

|Allergy|2018|1.4k

The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

|Allergy|2014|1.2k

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

|Allergy|2004|1.1k

Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma

|Clinical & Experimental Allergy|2004|520

New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure

|CHEST Journal|2004|497